×

Acorda CEO: EpiPen increase 'far in excess' of industry standard

4:38 PM ET Tue, 23 Aug 2016

Ron Cohen, Acorda Therapeutics President & CEO, and CNBC's Meg Tirrell discuss the outrage surrounding Mylan's EpiPen price hike and the general state of drug pricing and development.